SG11201908909PA - Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof - Google Patents
Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereofInfo
- Publication number
- SG11201908909PA SG11201908909PA SG11201908909PA SG11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA SG 11201908909P A SG11201908909P A SG 11201908909PA
- Authority
- SG
- Singapore
- Prior art keywords
- singapore
- international
- subject
- immune
- pct
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 7
- 239000002243 precursor Substances 0.000 title abstract 3
- 230000000638 stimulation Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 abstract 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omitia °nolo H01°1111111114 °nom oimIE (10) International Publication Number WO 2018/203833 Al (51) International Patent Classification: A61K 39/39 (2006.01) A61P 35/00 (2006.01) A61K 31/7056 (2006.01) A61P 37/04 (2006.01) A61P 31/00 (2006.01) GOJN 33/50 (2006.01) (21) International Application Number: PCT/SG2018/050219 (22) International Filing Date: 03 May 2018 (03.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201703628W 03 May 2017 (03.05.2017) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventors: GINHOUX, Florent; c/o Singapore Immunol- ogy Network, 8A Biomedical Grove, Singapore 138648 (SG). SEE, Chi Ee Peter; c/o Singapore Immunology Net- work, 8A Biomedical Grove, Singapore 138648 (SG). (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE W O 20 18/ 203833 Al (54) Title: METHODS FOR THE STIMULATION OF DENDRITIC CELL (DC) PRECURSOR POPULATION \"PRE-DC\" AND THEIR USES THEREOF (57) : The present invention relates to a method of treating or preventing an infection, a neoplastic disease or an immune-related disease in a subject in need thereof, the method comprising contacting a therapeutically effective or immuno-effective amount of an TLR9 agonist, specifically CpG oligodeoxynucleotide 2216 (CpG ODN), with a precursor dendritic cell (pre-DC), wherein the TLR9 agonist stimulates the pre-DC to secrete one or more cytokines such as TNF-alpha and IL-12p40, to thereby activate or increase the subject's immune response for treating or preventing the infection, the neoplastic disease or the immune-related disease. The present invention also relates to immunogenic or adjuvant compositions comprising the TLR9 agonist. A method of diagnosing a deficient immune system in a subject, comprising contacting a sample comprising pre-DC from the subject with one or more TLR 9 agonists and kits thereof are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201703628W | 2017-05-03 | ||
PCT/SG2018/050219 WO2018203833A1 (en) | 2017-05-03 | 2018-05-03 | Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908909PA true SG11201908909PA (en) | 2019-10-30 |
Family
ID=64014506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908909P SG11201908909PA (en) | 2017-05-03 | 2018-05-03 | Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210100897A1 (en) |
EP (1) | EP3618860A4 (en) |
CN (1) | CN110869048A (en) |
SG (1) | SG11201908909PA (en) |
WO (1) | WO2018203833A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
EP1556077A2 (en) * | 2002-10-29 | 2005-07-27 | Coley Pharmaceutical Group, Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
WO2005023982A2 (en) * | 2003-05-28 | 2005-03-17 | Univ. Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients |
US20090041808A1 (en) * | 2004-12-09 | 2009-02-12 | Osaka University | Detection/Measurement Of Malaria Infection Disease Utilizing Natural Immunity By Hemozoin Induction, Screening Of Preventative Or Therapeutic Medicine For Malaria Infection Disease, And Regulation Of Natural Immunity Induction |
EP2548571A1 (en) * | 2011-07-22 | 2013-01-23 | Institut Curie | Compositions having means for targeting at least one antigen to dendritic cells |
US11630103B2 (en) * | 2016-08-17 | 2023-04-18 | The Broad Institute, Inc. | Product and methods useful for modulating and evaluating immune responses |
-
2018
- 2018-05-03 US US16/610,461 patent/US20210100897A1/en active Pending
- 2018-05-03 SG SG11201908909P patent/SG11201908909PA/en unknown
- 2018-05-03 WO PCT/SG2018/050219 patent/WO2018203833A1/en unknown
- 2018-05-03 EP EP18795003.5A patent/EP3618860A4/en active Pending
- 2018-05-03 CN CN201880044972.7A patent/CN110869048A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3618860A1 (en) | 2020-03-11 |
WO2018203833A1 (en) | 2018-11-08 |
US20210100897A1 (en) | 2021-04-08 |
CN110869048A (en) | 2020-03-06 |
EP3618860A4 (en) | 2020-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804506RA (en) | Systems and methods for rendering multiple levels of detail | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201906235YA (en) | Narrowband time-division duplex frame structure for narrowband communications | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201804496UA (en) | Recombinant zika vaccines | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201804916PA (en) | Three-dimensional polymer networks with channels situated therein | |
SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
SG11201907701YA (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
SG11201901272WA (en) | Mesenchymal cell-derived exosomes to treat neurological disorders | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201809865RA (en) | Break analysis apparatus and method | |
SG11201407679PA (en) | Manufacture of degarelix |